PetMed Express reported a significant 19.4% year-over-year decline in net sales for Q2 2026, primarily due to lower prescription medication sales. Despite this, the company narrowed its net loss to $6.4 million, driven by cost reductions, indicating a mixed financial picture with ongoing operational challenges but some progress on profitability.
PetMed Express (PETS) reported a substantial 19.4% drop in Q2 2026 net sales, falling to $35.8 million from $44.4 million in the prior year. This decline, attributed to lower prescription medication sales and increased promotional usage, signals continued headwinds for its core business. While the net loss improved from $8.5 million to $6.4 million due to reduced expenses, the underlying revenue weakness is a significant concern. This filing primarily affects PETS shareholders, indicating ongoing operational struggles in its direct-to-consumer pharmacy segment. Short-term, the market may react negatively to the revenue miss, but the reduced net loss and focus on cost reduction could offer a glimmer of long-term hope if the company can stabilize sales. The key risk for traders is the continued erosion of sales, despite management's efforts to improve profitability and reduce customer acquisition costs.